nandrolone phenylpropionate side effects
Composition Active substance nandrolone phenylpropionate side effects – 20 mg (in the form of pellets – 0.235 g containing mannitol, sucrose, sodium lauryl sulfate, sodium hydrogen phosphate (disodium phosphate dibasic), calcium carbonate, lactose, hypromellose (hydroxypropylmethyl cellulose), methacrylic acid-ethyl acrylate copolymer (copolymer acid methacrylic L30D), propylene glycol, diethyl phthalate, cetyl alcohol, sodium hydroxide (sodium hydroxide), polysorbate-80 (Tween-80), povidone (polyvinylpyrrolidone), titanium dioxide, talc.
Body and cap: iron oxide red (E172), titanium dioxide (E171), methyl parahydroxybenzoate (methyl hydroxybenzoate), propyl parahydroxybenzoate (propyl), gelatin. Hard gelatin capsules or №2. Body and cap: iron oxide red (E172), titanium dioxide (E171), gelatin.
Opaque capsule №2. The body of light pink color, cap pinkish brown. The contents of capsules – pellets from white to almost white.
means lowering the secretion of gastric glands – proton pump inhibitor
ATC code: A02VS01
The pharmacological action of
proton pump inhibitor, reduces the acid production – inhibits the activity of H + / K + -ATPase in the parietal cells of the stomach and thereby blocks the final step of acid secretion. The drug and prodrug is activated in the acidic environment of the secretory canaliculi of the parietal cell.
It reduces basal and stimulated secretion regardless of the nature of the stimulus. Antisecretory effects after administration of 20 mg occurs within the first hours, the maximum – in 2 hours. 50% inhibition of maximal secretion lasts 24 hours.
A single dose per day provides a quick and effective inhibition of daytime and nocturnal gastric secretion, reaches its maximum after 4 days of treatment and disappear by the end of 3-4 days after admission. In patients with ulcer duodenum 12 receiving 20mg of nandrolone phenylpropionate side effects supports intragastric acidity index (pH) at 17 for 3 hours.
The absorption of the drug – high, the time to reach maximum concentration (T Cmax ) – 0.5-3.5 hours, bioavailability – 30-40% (in hepatic failure increases to nearly 100%); possessing highly lipophilic, easily penetrate the parietal cells of the stomach, the connection with plasma proteins – 90-95% (albumin and acid α1-glycoprotein).
The half-life (T1 / 2) – 0,5-1 hour (for liver failure – 3 hours), clearance -500-600 ml / min. Almost completely metabolized in the liver with the participation of the CYP2C19 enzyme system, to form a 6 metabolites (gidroksiomeprazol, sulfide and sulfone derivatives, etc.), A pharmacologically inactive. It is an inhibitor of the isozyme CYP2C19. Excretion by the kidneys (70-80%) and the bile (20-30%). In chronic renal insufficiency excretion is reduced in proportion to the decrease in creatinine clearance. In elderly patients deducing decreases, bioavailability increases.
Indications for use.
Peptic ulcer and 12 duodenal ulcer (including relapse prevention), reflux esophagitis, hypersecretory conditions (Zollinger-Ellison syndrome, stress ulcers, gastrointestinal tract, multiple endocrine adenomatosis, systemic mastocytosis); NSAID gastropathy. Helicobacter pylori eradication in infected patients with gastric ulcer and 12 duodenal ulcer (in a combination therapy).